MetrioPharm-Blog
Search this website
  • Start
  • Editorial Staff
  • Company
  • Contact
  • DeutschDeutsch
  • EnglishEnglish
slide
Read More

Einblicke in den MetrioPharm-Firmenalltag

Abonnieren Sie unseren Blog-Newsletter!
slide
Read More

Insights into the MetrioPharm company

Subscribe to our blog newsletter!
slide
Read More

Über MetrioPharm

Wir entwickeln neue Medikamente gegen chronische Immunerkrankungen
slide
Read More

About MetrioPharm

We are developing new drugs for chronic immune diseases
01/09/
2020

MetrioPharm in the FAZ

by Ralf Haubert, Marketing Manager, MetrioPharm
by General
No Comments on MetrioPharm in the FAZ

Article from the Frankfurter Allgemeine Zeitung from December 24, 19:

© All rights reserved. Frankfurter Allgemeine Zeitung GmbH, Frankfurt.
To the newspaper article in the archive of the Frankfurter Allgemeine
  • share 
  • share 

Related Posts:

The Full Potential of MP1032: MetrioPharm Publishes Annual Report 2021

Metriopharm's early intervention treatment for mild-moderate COVID- 19

"The Path to the Clinical Trial"

Contact


Eva Brysch
Head of Investor Relations & Corporate Communications
invest@metriopharm.com


Ralf Haubert
Marketing Manager
blog@metriopharm.com

Newsletter subscription

Register here for blogging news via e-mail-newsletter.

Recent Posts

  • The Full Potential of MP1032: MetrioPharm Publishes Annual Report 2021
  • Metriopharm’s early intervention treatment for mild-moderate COVID- 19
  • “The Path to the Clinical Trial”
  • SARS-CoV-2 and Mitochondrial Health
  • “Breaking the vicious COVID cycle at an early stage”

Categories

  • Annual Report
  • Ask the CEO
  • Employees
  • Events
  • General
  • HORIZON, iMPact
  • Opinion
  • Phase II Psoriasis
  • Preclinical COPD Study
  • Research results

Archives

  • May 2022
  • January 2022
  • May 2021
  • November 2020
  • April 2020
  • January 2020
  • December 2019
  • October 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • February 2019
  • December 2018
  • November 2018
  • October 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018

RSS Press Releases

  • 08.12.2022 MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients
  • 12.10.2022 MetrioPharm Starts Preclinical Experiments in Duchenne Muscular Dystrophy (DMD)
  • 29.07.2022 Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19
  • 02.03.2022 MetrioPharm surpasses 50% of enrollment in Phase II study in COVID-19

RSS Investor Relations News

  • MetrioPharm Investor Relations News QIV 2022
  • MetrioPharm Investor Relations News QIII 2022
  • MetrioPharm Investor Relations News QII 2022
  • MetrioPharm Investor Relations News QI 2022

MetrioPharm AG

  • Imprint
  • Privacy policy

Switzerland (HQ)

MetrioPharm AG
Bleicherweg 10
8002 Zurich

Phone: +41 (44) 562 03 35

Germany (R&D)

MetrioPharm Deutschland GmbH
Am Borsigturm 100
13507 Berlin

Phone: +49 (30) – 3384 395 02

© MetrioPharm AG 2019